<DOC>
	<DOCNO>NCT01227629</DOCNO>
	<brief_summary>The purpose trial evaluate safety different dos BIBR 1048 , alone combination acetylsalicylic acid ( ASA ) , determine rate bleed adverse event . A secondary objective trial evaluate anticoagulant effect different dos BIBR 1048 , base reduction plasma concentration D-dimer , laboratory marker activate coagulation patient atrial fibrillation ( AF ) , correlate bleeding event pharmacokinetic ( PK ) pharmacodynamic ( PD ) data .</brief_summary>
	<brief_title>PETRO Stroke Prevention Patients With AF Treatment With Dabigatran , With Without Aspirin , Compared Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion 1 . Nonrheumatic atrial fibrillation . 2 . Coronary artery disease ( CAD ) , document previous myocard infarction ( MI ) , angina , positive stress test , previous coronary intervention bypass surgery , atherosclerotic lesion ( ) diagnose coronary angiography ) consider one several possible qualify risk factor . After recruitment ca . 30 % , protocol amendment 4 issue CAD consider one several possible qualify risk factor , 2. see ( 3 f ) . 3 . An additional risk factor stroke , i.e . one follow conditions/events : 1. hypertension ( define systolic bloodpressure ( SBP ) &gt; 140 mmHg and/or diastolic bloodpressure ( DBP ) &gt; 90 mm Hg ) require antihypertensive medical treatment . 2. diabetes mellitus ( type I II ) . 3. symptomatic heart failure leave ventricular dysfunction ( ejection fraction ( EF ) &lt; 40 % ) . 4. previous ischemic stroke transient ischemic attack . 5. age great 75 year . 6. history coronary artery disease ( amendment 4 ) 4 . Treatment warfarin vitamin K dependent anticoagulant least 8 week prior inclusion . International normalise ratio ( INR ) within therapeutic range ( i.e . INR 2.0 3.0 ) visit 1 otherwise visit reschedule . 5 . Age &gt; = 18 year entry . 6 . Written , inform consent . Exclusion criteria 1 . Valvular heart disease . 2 . Planned cardioversion . 3 . Recent ( = &lt; 1 month ) myocardial infarction , stroke transient ischemic attack ( TIA ) , patient receive coronary stent within last 6 month . 4 . Intolerance contraindication acetylsalicylic acid ( ASA ) . 5 . Any contraindication anticoagulant therapy . 6 . Major bleed within last 6 month ( gastrointestinal ( GI ) hemorrhage ) . 7 . Severe renal impairment ( estimate glomerular filtration rate ( GFR ) = &lt; 30 mL/min ) . 8 . Uncontrolled hypertension ( SBP &gt; 180 mmHg and/or DBP &gt; 100 mmHg ) . 9 . Abnormal liver function define aspartataminotransferase ( AST ) , alaninaminotransferase ( ALT ) , serum bilirubin alkaline phosphatase ( AP ) reference range , history liver disease . 10 . Women pregnant childbearing potential refuse use medically acceptable form contraception throughout study . 11 . Patients receive investigational drug within last 30 day . 12 . Patients schedule major surgery invasive procedure may cause bleeding , major surgery percutaneous coronary intervention ( PCI ) within 6 week . 13 . Patients consider unreliable investigator . 14 . Another indication anticoagulant treatment . 15 . Patients suffer anemia . 16 . Patients suffer thrombocytopenia . 17 . Any condition , discretion investigator , would allow safe participation study . 18 . Concomitant treatment antiplatelet agent ASA . 19 . Recent malignancy radiation therapy ( = &lt; 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>